Latest Regulatory News

Astral Resources will issue Estrella Resources 20 million shares valued at $3 million to acquire nickel rights across five tenements within the broader Mandilla development footprint. Completion is targeted for 12 October, but remains conditional on shareholder, regulatory and third-party approvals.

Estrella Resources has agreed to divest its nickel rights across five Western Australian tenements for 20 million Astral Resources shares valued at $3 million. The deal remains conditional, but would sharpen Estrella’s focus on its Timor-Leste exploration portfolio while preserving exposure to Astral’s equity upside.

Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.

OD6 Metals has secured A$6.92 million from institutional and sophisticated investors to advance drilling, bulk sampling and resource definition at its Quinn Fluorspar Project in Nevada. The funding also sets up a proposed rebrand to Adaven, but brings dilution and a substantial package of shareholder approvals.

Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Famien Resources will sell its West Yilgarn exploration portfolio to Voltaic Strategic Resources for $330,000 upfront, with a further $2 million tied to future gold resource milestones. The deal gives Famien immediate cash while leaving the larger deferred payment dependent on exploration success by the buyer.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

Finder Energy has extended the Kuda Tasi and Jahal project’s Final Investment Decision deadline to 30 November, after widening its international EPCI tender process. The company says debt financing is nearing its final stages, but the delay adds another checkpoint before its late-2027 drilling target.

HealthCo Healthcare and Wellness REIT has signed binding agreements for new leases covering its remaining 10 Healthscope hospitals, subject to final approvals. The resolution allows HCW to reinstate quarterly distributions while reducing its largest tenant concentration from 57% to 31%.

Brazilian Critical Minerals has signed binding agreements to acquire 90% of a Brazilian magnesium sulphate producer, aiming to secure a key input for its Ema rare earth project. The strategy offers greater supply-chain control, but the plant requires restructuring and carries estimated legacy liabilities of R$15.3 million.